Compounds useful as chemokine receptor antagonists

Details Compounds useful as chemokine receptor antagonists Compounds useful as chemokine receptor antagonists

Filed on

2005-12-28

Date issued

2009-12-22

Examiner

Wilson, James O (Department: 1624)

Patent Class

Drug, bio-affecting and body treating compositions

SubClass

Designated organic active ingredient containing

SubSubClass

Heterocyclic carbon compounds containing a hetero ring...

Other Related Categories

C544S358000

Type

Reexamination Certificate

Status

active

Patent number

07635698

Description

ABSTRACT:
The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided:or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer, and osteolytic bone disorders.

REFERENCES:
patent: 3265698 (1966-08-01), Allen, Jr. et al.
patent: 5338852 (1994-08-01), Efange et al.
patent: 5756508 (1998-05-01), Thompson et al.
patent: 5773442 (1998-06-01), Akamatsu et al.
patent: 5789420 (1998-08-01), Efange et al.
patent: 5876694 (1999-03-01), Efange et al.
patent: 5985878 (1999-11-01), Stokbroekx et al.
patent: 6057324 (2000-05-01), Matsumoto et al.
patent: 6166037 (2000-12-01), Budhu et al.
patent: 6521621 (2003-02-01), Janssens et al.
patent: 6642226 (2003-11-01), Kolczewski et al.
patent: 6906072 (2005-06-01), Yamamoto et al.
patent: 6930104 (2005-08-01), Kakihana et al.
patent: 6977265 (2005-12-01), Du Bois et al.
patent: 7291618 (2007-11-01), Hulin et al.
patent: 2002/0151547 (2002-10-01), Kolczewski et al.
patent: 2003/0229121 (2003-12-01), Du Bois et al.
patent: 2004/0157850 (2004-08-01), Kakihana et al.
patent: 2004/0186135 (2004-09-01), Dolle et al.
patent: 2004/0220193 (2004-11-01), Yamamoto et al.
patent: 2005/0137211 (2005-06-01), Blanco et al.
patent: 2005/0256310 (2005-11-01), Hulin et al.
patent: 2006/0040950 (2006-02-01), Janssens et al.
patent: 2006/0079498 (2006-04-01), Hulin et al.
patent: 2006/0084658 (2006-04-01), Yamamoto et al.
patent: 2006/0128721 (2006-06-01), Janssens et al.
patent: 2006/0167008 (2006-07-01), Janssens et al.
patent: 2006/0172994 (2006-08-01), Carson et al.
patent: 2006/0217392 (2006-09-01), Anilkumar et al.
patent: 2007/0021611 (2007-01-01), McGuinness et al.
patent: 2007/0054919 (2007-03-01), Rosenblum et al.
patent: 2007/0099897 (2007-05-01), Hulin et al.
patent: 2007/0161664 (2007-07-01), Hulin et al.
patent: 0121972 (1984-10-01), None
patent: 0542363 (1993-05-01), None
patent: 0810215 (1997-12-01), None
patent: 0905129 (1999-03-01), None
patent: 1080680 (1967-08-01), None
patent: 43020190 (1968-08-01), None
patent: WO 93/10091 (1993-05-01), None
patent: WO 93/24457 (1993-12-01), None
patent: WO 97/16192 (1997-05-01), None
patent: WO 97/26258 (1997-07-01), None
patent: WO 99/09984 (1999-03-01), None
patent: WO 00/66558 (2000-11-01), None
patent: WO 02/062784 (2002-08-01), None
patent: WO 02/079194 (2002-10-01), None
patent: 1254895 (2002-11-01), None
patent: WO 03/004487 (2003-01-01), None
patent: WO 03/020716 (2003-03-01), None
patent: WO 03/033490 (2003-04-01), None
patent: WO 03/045937 (2003-06-01), None
patent: 1382598 (2004-01-01), None
patent: WO 2004/033428 (2004-04-01), None
patent: WO 2004/056770 (2004-07-01), None
patent: WO 2004/056772 (2004-07-01), None
patent: WO 2004/056799 (2004-07-01), None
patent: WO 2004/082623 (2004-09-01), None
patent: WO 2004/110415 (2004-12-01), None
patent: WO 2005/030188 (2005-04-01), None
patent: WO 2005/101838 (2005-10-01), None
patent: WO 2005/116014 (2005-12-01), None
patent: WO 2006/008644 (2006-01-01), None
patent: WO 2006/088840 (2006-08-01), None
patent: WO 2006/088919 (2006-08-01), None
patent: WO 2006/088921 (2006-08-01), None
International Search Report dated Jun. 1, 2006 issued in PCT Application No. PCT/US05/047327, which corresponds to U.S. Appl. No. 11/320,298.
Assaad, Thaer, et al., “Synthesis and in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular acetylcholine transporter ligands,”Bioorganic&Medicinal Chemistry Letters, vol. 16, No. 10 (2006) pp. 2654-2657.
Coffeen, Paul R., et al., “Measurement of functional cholinergic innervation in rat heart with a novel vesamicol receptor ligand,”Nuclear Medicine&Biology, vol. 23, No. 7 (1996) pp. 923-926.
Custers, Franciscus G. J., et al., “Vesamicol and some of its derivatives: Questionable ligands for selectively labelling acetylcholine transporters in rat brain,”European Journal of Pharmacology, vol. 338, No. 2 (1997) pp. 177-183.
Efange, S.M.N., et al., “Nonsymmetrical bipiperidyls as inhibitors of vesicular acetylcholine storage,”Journal of Medicinal Chemistry, vol. 36, No. 8 (1993) pp. 985-989.
Efange, S.M.N, et al., “Synthesis and tissue distribution of (m[125l]iodobenzyl)trozamicol ([125l]MIBT): potential radioligand for mapping central cholinergic innervation,”Journal of Medicinal Chemistry, vol. 36, No. 12 (1993) pp. 1754-1760.
Efange, S.M.N., et al., “p-[18F]fluorobenzyltrozamicol ([18F]FBT): molecular decomposition-reconstitution approach to vesamicol receptor radioligands for positron emission tomography,”Applied Radiation and Isotopes, vol. 45, No. 4 (1994) pp. 465-472.
Efange, Simon M. N., et al., “Vesamicol analogues as sigma ligands,”Biochemical Pharmacology, vol. 49, No. 6 (1995) pp. 791-797.
Efange, Simon M. N., et al., “Age-related diminution of dopamine antagonist-stimulated vesamicol receptor binding,”The Journal of Nuclear Medicine, vol. 37, No. 7 (Jul. 1996) pp. 1192-1196.
Efange, Simon M. N., et al., “N-hydroxyalkyl derivatives of 3β-phenyltropane and 1-methylspirol[1H-indoline-3,4′-piperidine]: vesamicol analogues with affinity for monoamine transporters,”Journal of Medicinal Chemistry, vol. 40, No. 24 (1997) pp. 3905-3914.
Efange, Simon M. N., et al., “The vesamicol receptor ligand (+)-meta-[125l]iodobenzyltrozamicol {(+)-[125I]-MIBT} reveals blunting of the striatal cholinergic response to dopamine D2 receptor blockade in the 6-hydroxydopamine (6-OHDA)-lesioned rat: possible implications for Parkinson's disease,”Life Sciences, vol. 58, No. 16 (1996) pp. 1367-1374.
Efange, S.M.N., et al., “Vesicular acetylcholine transporter density and Alzheimer's disease,”Neurobiology of Aging, vol. 18, No. 4 (1997) pp. 407-413.
Efange, S.M.N., et al., “(+)-p-([18F]fluorobenzyl)spirotrozamicol {(+)-[18F]spiro-FBT): synthesis and biological evaluation of a high-affinity ligand for the vesicular acetylcholine transporter (VAChT),”Nuclear Medicine&Biology, vol. 26, No. 2 (1999) pp. 189-192.
Gage, H. Donald, et al., “Reproducibility of repeated measures of cholingeric terminal density using [18F](+)-4-fluorobenzyltrozamicol and PET in the Rhesus monkey brain,”Journal of Nuclear Medicine, vol. 41, No. 12 (2000) pp. 2069-2076.
Gage, H. Donald, et al., “Morphine-induced spinal cholinergic activation: in vivo imaging with positron emission tomography,”Pain, vol. 91, No. 1-2 (2001) pp. 139-145.
Gaina, C., et al., “Polyimides containing 4,4′-bipyridinium units,”Journal of Applied Polymer Science, vol. 94 (2004) pp. 2091-2100.
Hiessbock, Romana, et al., “Synthesis and in vitro multidrug resistance modulating activity of a series of dihydrobenzopyrans and tetrahydroquinolines,”Journal of Medicinal Chemistry, vol. 42, No. 11 (1999) pp. 1921-1926.
Khare, A. B., et al., “N-(3-iodophenyl)trozamicol (IPHT) and related inhibitors of vesicular acetylcholine transport: synthesis and preliminary biological characterization,”Nuclear Medicine&Biology, vol. 26, No. 6 (1999) pp. 609-617.
Mach, Robert H., et al., “Imaging of cholinergic terminals using the radiotracer [18F](+)-4-fluorobenzyltrozamicol: in vitro binding studies and positron emission tomography studies in nonhuman primates,”Synapse, vol. 25, No. 4 (1997) pp. 368-380.
Mach, Robert H., et al., “[18F]4-fluorobenzyl iodide as a useful precursor in PET research: application in the development of dopaminergic and cholinergic radiotracers,”Synthesis and Applications of Isotopically Labelled Compounds, vol. 8 Proceedings of the International Symposium, Boston, MA, USA, Jun. 1-5, 2003 (2004), meeting date 2003, pp. 183-186, edit

Affiliated with

Also associated with

Rating

Compounds useful as chemokine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds useful as chemokine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds useful as chemokine receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4097237